Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Commercial Japan United States

Strong Xtandi Drives Astellas To Brighter Outlook

Executive Summary

Japanese firm unveils new capital investment program for novel biologics including antibodies and cell therapies as it ups full-year forecasts on strong US and global growth for Xtandi after a solid first half.

You may also be interested in...



Hello NMPA: China Approval For Astellas's Xtandi, Keytruda Set For Fourth Indication

Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.

Astellas Exercises Option To Acquire Potenza, For Up To $405m

Astellas has exercised an option to acquire Potenza, paying up to $404.7m in cash for the private US venture in a deal that will boost its presence in immuno-oncology.

First Approval Globally For Gilteritinib, In Japan For AML

First nod globally for Astellas's FLT3 inhibitor set to further increase competition in AML space, but commercial opportunity in  launch market Japan looks set to be limited.

Table

View full table

Related Content

Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Commercial Japan United States
Latest Headlines

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

Precision Keeps Faith In Duchenne Gene-Editing After Lilly’s Exit

See All
UsernamePublicRestriction

Register

SC124117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By